NuView Life Sciences Secures $90 Million Capital Commitment from Global Emerging Markets for Development of NV-VPAC1™ Cancer Portfolio

August 6, 2020

Willkie represented NuView in the transaction.

Willkie represented NuView Life Sciences Inc. in securing a $90 million capital commitment from GEM Global Yield LLC SCS, a Luxembourg-based private, alternative investment group, announced on August 3.

Under the share subscription facility, GEM has agreed to purchase common stock from NuView on a firm commitment basis for an aggregate value of $90 million upon NuView filing a Registration Statement with the U.S. Securities and Exchange Commission. The agreement provides NuView a 36-month drawdown period.

In connection with the share subscription facility, NuView has also granted GEM a warrant to purchase up to the number of shares of NuView’s common stock equal to 3.5% of the total number of shares of common stock outstanding as of NuView’s public listing date.

NuView will use funds to complete a 600-patient in vitro double-blind clinical trial in accordance with the U.S. Food and Drug Administration approval process. NuView will also allocate funds for its in vivo diagnostics and Theranostic programs.

The Willkie deal team was led by corporate partner Robert Rizzo and included associates Tej Prakash and Katherine Dorris. Partners Michael Katz and Matthew Makover and associate Kelsie Kelly also provided assistance.